On September 26, the Cancer Prevention & Research of Texas (CPRIT) announce the latest round of funding opportunities. The awards must be received by CPRIT between October 16 – January 15, 2020.
They are as follows:
Description: Supports investigator-initiated research projects designed to understand the reasons for the increased incidence of hepatocellular cancer (HCC) in Texas, to identify risk factors for cirrhosis and HCC, to identify biomarkers for HCC early detection, and to develop and implement prevention and early detection strategies.
Award: CPRIT plans to make multiple awards in response to this RFA. Up to $500,000 per year (total costs)
Maximum duration: 5 years.
Description: Solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with and survivors of cancer.
Award: Up to $4,000,000 (total costs)
Maximum duration: 5 years
*An institution may submit only 1 application (1 new, 1 renewal, or 1 resubmission) under this RFA during this funding cycle.
NEW Award! NEW institutional limit!**
Description: Solicits applications from institutions to provide cancer physicians early in their academic career the opportunity to develop clinical research skills and to gain experience in advanced methods and experimental approaches needed to become clinical investigators; to provide an opportunity to establish a partnership with a laboratory-based collaborator in order to design and conduct correlative studies needed to interpret the outcome of an interventional trial; to provide the protected time from clinical responsibilities required to develop and conduct investigator initiated clinical trials; and to increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies, capitalizing on basic discoveries and translating them through conduct of innovative clinical trials involving cancer patients or individuals at risk for cancer.
Award: Up to $1,5000,000 (total costs)
Maximum duration: 5 years.
**An institution may submit only 2 applications under this RFA during this funding cycle.
Description: Provides short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers.
Award: Up to $250,000 (total costs)
Maximum duration: 2 years.
***A PI may submit only 1 new or resubmission application under this RFA during this funding cycle.
One Co-PI may be included. An individual may serve as a Co-PI in more than 1 application but should ensure that he or she could dedicate adequate time and effort should more than 1 application be funded. The Co-PI must reside in Texas for the period of the time that the research that is the subject of the grant application is conducted.
For the two (2) Institutional Limit Awards, (Core Facility Support and Early Clinical Investigator Awards), interested investigators at UTMB should send a one-page abstract and biosketches of all proposed PIs or Co-Is to Ericia Huff on or before noon, September 23, 2019. The Grant Review & Oversight (GRO) Committee will review the abstracts and return a decision for the institutional submission before October 11, 2019. All questions concerning the limited submission process should be routed to Ms. Huff.